Sonire Therapeutics Inc. - Pioneering Next-Generation HIFU Therapy for Pancreatic Cancer

Company Overview (Updated April 2026)

Sonire Therapeutics Inc. is a U.S.-based clinical-stage medical device company headquartered in Palo Alto, California. Founded in February 2020 in Tokyo, Japan by Tohru Satoh (President & CEO), Jun Okamoto (Vice President & COO), and Shin Yoshizawa, the company is pioneering next-generation High-Intensity Focused Ultrasound (HIFU) therapy systems for the treatment of intractable solid tumors. The company's mission is to "bring a new future to cancer patients" through innovative, non-invasive acoustic engineering.

Technology Foundation: Sonire's technology builds upon over a decade of research and clinical know-how developed at Tokyo Women's Medical University, Tohoku University, and Tokyo Medical University, supported by Japan's NEDO Deep-Tech Startup Support Program with funding of JPY 971 million (2023-2025).

History & Development

Key Milestones:

- 2007-2020: Academic research foundation established through collaborative work at Tokyo Women's Medical University, Tohoku University, and Tokyo Medical University under Japan's NEDO and FIRST programs

- February 2020: Company founded in Tokyo, Japan

- 2021-2022: Secured Series A and B funding from Higin Capital, Mitsubishi UFJ Capital, SBI Investment, and others

- February 2023: Initiated SUNRISE-I randomized Phase 2 clinical study (NCT05601323) for unresectable pancreatic cancer at seven leading Japanese hospitals

- December 2023: Published foundational clinical research on Sonodynamic Therapy (SDT) using HIFU in Ultrasound in Medicine & Biology journal

- November 2024: Received FDA Breakthrough Device Designation for HIFU pancreatic cancer treatment system

- 2025: Relocated headquarters to Palo Alto, California; established Japan subsidiary in Chuo-ku, Tokyo

- April 15, 2026: Closed $18 million Series A financing led by Santé Ventures to advance U.S. clinical development

Core Technology & Products

Suizenji HIFU Therapy System (Flagship Product)

Device Description:

The Suizenji system is a next-generation ultrasound-guided HIFU therapy device designed for precise, non-invasive, outpatient thermal ablation of solid tumors. Unlike conventional ultrasound-guided HIFU systems, Sonire's solution provides clear real-time visualization of the treatment site, requires no anesthesia, and can be performed on an outpatient basis in approximately 20 minutes.

Key Technical Innovations:

- Real-Time Imaging Guidance: Advanced ultrasound imaging with patented noise-cancellation system

- Cavitation Bubble Visualization: Proprietary technology to visualize and control cavitation bubbles for enhanced safety

- Robot-Assisted Positioning Platform: Automated positioning for precise targeting

- Rapid Multi-Focus Scanning: Advanced capabilities for effective thermal ablation

- Single-Operator Design: Requires only one physician to administer treatment, lowering cost and staff burden for hospitals

Mechanism of Action

The HIFU system focuses ultrasound waves emitted from outside the body to thermally coagulate tissue at the target site. Key features include:

- Non-Invasive: No incisions required; energy delivered through intact skin

- Radiation-Free: No radiation exposure, allowing patients to receive treatment repeatedly

- Short-Time Treatment: Procedure completed in approximately 20 minutes

- Outpatient Procedure: No anesthesia required; patients can return home same day

Sonodynamic Therapy (SDT)

Building on the HIFU platform, Sonire is also developing Sonodynamic Therapy (SDT) that combines focused ultrasound with specific drugs (Epirubicin micelle/K-912). A first-in-human clinical trial published in Ultrasound in Medicine & Biology demonstrated this approach in 12 cases of unresectable pancreatic cancer and intrahepatic cholangiocarcinoma.

Clinical Development

SUNRISE-I Study (NCT05601323)

Study Design: Randomized controlled trial comparing HIFU with chemotherapy versus chemotherapy alone in patients with unresectable pancreatic cancer

- Primary Endpoint: Overall survival

- Patient Population: Patients refractory or intolerant to first-line chemotherapy

- Sites: Seven leading Japanese hospitals

- Status: Active, not recruiting (as of 2026)

- Expected Completion: May 2027

- Significance: World's first randomized HIFU trial for pancreatic cancer

Preliminary Clinical Evidence

An academic-led study using a prototype HIFU system (MoonShot-2) demonstrated a 66% disease control rate in patients with advanced or refractory pancreatic and biliary tract cancers in a sonodynamic therapy (SDT) setting. These findings informed the development of Sonire's current Suizenji system.

Regulatory Status

- FDA Breakthrough Device Designation: Granted November 2024 for pancreatic cancer treatment

- U.S. Clinical Trials: Planning to initiate clinical trials for unresectable pancreatic cancer in the U.S. following the April 2026 funding round

- Japan: Licensed as First Class Medical Device Marketing Authorization Holder and Medical Device Manufacturer

- EU/Other Markets: Future expansion planned

Corporate Information (2026)

Company Profile

Legal Name: Sonire Therapeutics Inc.

Founded: February 2020

Headquarters: 214 Homer Ave, Palo Alto, CA 94301, USA

Japan Subsidiary: 803 Nihonbashi Life Science Building 2, 3-11-5 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan

CEO & President: Tohru Satoh

VP & COO: Jun Okamoto

Employees: 27 (as of 2026)

Fiscal Year End: December

Capital: JPY 100 million

Patents: 25 issued, 22 pending

Total Funding Raised: $21.8 million (cumulative)

Website: www.sonire-therapeutics.com

Board of Directors

- President & CEO: Tohru Satoh

- Vice President & COO: Jun Okamoto

- External Board Member: Dennis McWilliams (Managing Director, Santé Ventures)

- External Board Member: Hiroko Kimura (Principal, Fast Track Initiative)

- External Auditor: Tomohiro Anzai (Fast Track Initiative)

Funding History

- Series A/B (2021-2022): Higin Capital (lead), Mitsubishi UFJ Capital, SBI Investment, others

- Grant (September 2023): Deep Tech Startup Support Program (NEDO) - JPY 971 million

- Series A Extension (April 2026): $18 million led by Santé Ventures, with FTI, Nomura SPARX Investment, and SBI Investment

Market Opportunity

Disease Burden:

- Pancreatic Cancer: 5-year survival rate of only 12%; one of the most lethal cancers with limited treatment options

- Unmet Medical Need: High unmet need due to lack of established standard local therapy options for intractable pancreatic cancer

- Therapeutic Advantage: HIFU offers minimally invasive treatment with low side effect profile and no radiation exposure, enabling repeat treatments

2026 Strategic Priorities

- Complete SUNRISE-I Trial: World's first randomized HIFU trial for pancreatic cancer in Japan

- U.S. Clinical Development: Initiate U.S. clinical trials and progress toward U.S. regulatory approval

- Global Commercialization: Advance global commercialization efforts for the Suizenji HIFU system

- Pipeline Expansion: Planning clinical studies for metastatic liver cancer in Japan and other oncology indications

- Platform Development: Continue development of Sonodynamic Therapy (SDT) combining HIFU with drug delivery systems

Key Differentiators

- Real-Time Visualization: Patented noise-cancellation and cavitation bubble visualization solve core challenges that have limited conventional HIFU systems

- Anesthesia-Free: Outpatient procedure requiring no anesthesia, reducing patient burden and healthcare costs

- Single-Operator Efficiency: Robot-assisted platform requires only one physician, lowering staff burden

- Academic Foundation: Technology built on over a decade of research at leading Japanese medical universities

- Regulatory Momentum: FDA Breakthrough Device Designation and first-in-kind randomized trial for pancreatic cancer

- Strong IP Position: 25 issued patents and 22 pending applications protecting core technology

Keywords: Sonire Therapeutics,HIFU,High-Intensity Focused Ultrasound,pancreatic cancer,Suizenji,sonic therapy,medical device,Palo Alto,Tohru Satoh,Santé Ventures,FDA Breakthrough Device,SUNRISE-I,Sonodynamic Therapy,SDT,thermal ablation